Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesTransplantHealthSpring Kidney Transplant Coverage | OpenPaye…
    Ask Trek AI about this page
    ModifiedHealthSpringPolicy SUR703.007

    Kidney Transplant

    Customize your policy alerts

    Sign up for healthspring Policy SUR703.007 alerts

    Get alerted when Policy SUR703.007 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage for living-donor, deceased-donor, and kidney retransplant procedures for carefully selected individuals with end-stage renal disease who meet the policy criteria, subject to the member’s benefit plan and applicable mandates.

    Policy Summary
    PayerHealthSpring
    PolicyKidney Transplant
    Policy CodePolicy SUR703.007
    Change TypeModified
    Effective DateMay 7, 2026
    Next Review DateN/A
    Key ActionReview the member’s benefit contract or Summary Plan Description for coverage, exclusions, and benefit limitations.
    SourceLink
    POLICY UPDATE CHANGES

    Kidney transplantation may be medically necessary for carefully selected individuals with end-stage renal disease, including eligible living- or deceased-donor transplants and qualifying retransplants.

    ESRDPrimary condition

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    2Donor types
    1Retransplant pathway
    TXState mandate
    All other situationsOutside covered circumstances

    Kidney Transplant Coverage Criteria

    Initial kidney transplantation

    Covered when the individual is carefully selected and has end-stage renal disease.

    • ONE of the following donor types

      • Living donor: Living-donor kidney transplant.
      • Deceased donor: Deceased (cadaveric)-donor kidney transplant.

    Kidney retransplantation

    Covered after failure of the primary kidney transplant when the individual meets kidney-transplantation criteria.

    • Prior transplant failure: The primary kidney transplant has failed.
    • Transplant eligibility: The individual meets criteria for kidney transplantation.

    Renal-specific listing and transplant timing

    Listing and transplant timing are guided by clinical circumstances and waiting-time rules.

    Listing and timing considerations

    • Waiting-time calculation: Waiting time uses the earliest date on which the candidate's GFR or measured or estimated creatinine clearance was less than or equal to 20 mL/min, or the date regularly administered dialysis began for end-stage renal disease.GFR or measured or estimated creatinine clearance ≤20 mL/min, or initiation of regular dialysis for ESRD
    • Earlier listing consideration: Consideration for listing may begin before the kidney-function threshold is reached, based on the anticipated time the individual may spend on the waiting list.
    • Transplant timing: When a living donor is available or preemptive deceased-donor transplantation is possible, cases should proceed when the eGFR is below 10 mL/min/1.73 m² in adults or 10 to 15 mL/min/1.73 m² in pediatric patients.

    Clinical evaluation considerations

    Evaluate patients with advanced chronic kidney disease for kidney transplantation.

    Kidney transplant evaluation: Patients with advanced chronic kidney disease, principally stage 4 or stage 5, should be evaluated for kidney transplantation.Stage 4: GFR 15 to 29 mL/min/1.73 m²; stage 5: GFR <15 mL/min/1.73 m²

    Dialysis is not required to be considered for kidney transplantation.

    Initial kidney transplantation

    May be considered medically necessary for a carefully selected individual with end-stage renal disease.

    Initial kidney transplant: The individual has end-stage renal disease and is carefully selected for kidney transplantation.

    The donor may be living or deceased (cadaveric).

    Retransplantation

    May be considered medically necessary after a failed primary kidney transplant when kidney-transplantation criteria are met.

    Kidney retransplantation: The individual has had a failed primary kidney transplant and meets criteria for kidney transplantation.

    Experimental, investigational, or unproven situations

    Kidney transplantation is considered experimental, investigational, and/or unproven outside the covered situations described above.

    Other situations: The indication is not transplantation for a carefully selected individual with end-stage renal disease and is not an eligible retransplant after a failed primary kidney transplant when transplantation criteria are met.

    Kidney transplantation in such circumstances is considered experimental, investigational, and/or unproven.

    For applicable Texas policies, coverage is prohibited for a human organ transplant or post-transplant care when the transplant operation is performed in China or another country known to have participated in forced organ harvesting. Coverage is also prohibited when the organ was procured through a sale or donation originating in China or another such country.

    Known current malignancy, including metastatic cancer, is a contraindication to solid-organ transplantation. Transplant candidacy may also be affected by a recent malignancy with a high risk of recurrence or a history of cancer with a moderate risk of recurrence, subject to the judgment of the transplant center.

    Other irreversible end-stage diseases not attributable to kidney disease are identified as a potential contraindication to transplantation. The transplant center should consider whether the additional disease would affect expected outcomes or the individual’s suitability for transplant.

    Kidney transplantation is considered experimental, investigational, and/or unproven when it is not performed for a carefully selected individual with end-stage renal disease or as a qualifying retransplant after failure of a primary kidney transplant.

    Coding and Clinical Thresholds

    CPT CodesCPT
    50300
    50320
    50323
    50325
    50327
    50328
    50329
    50340
    50360
    50365
    1–10 of 12
    1/2
    HCPCS CodesHCPCS
    S2152
    Waiting-Time Calculation
    Waiting-time thresholdGFR or measured or estimated creatinine clearance ≤20 mL/min
    Alternative timing eventInitiation of regularly administered dialysis for end-stage renal disease
    Listing considerationListing consideration may start before this threshold based on anticipated waiting-list time
    Adult Pre-emptive or Living-Donor Timing
    Adult timing thresholdeGFR <10 mL/min/1.73 m²
    Applicable situationA living donor is available or pre-emptive deceased-donor transplantation is possible

    Provider and Coverage Actions

    Documentation Required

    Review the Member Benefit Contract

    Review the member’s benefit contract or Summary Plan Description alongside this policy to determine defined coverage versus non-coverage, exclusions, and limitations such as dollar or duration caps. Procedure and supply codes listed in the policy do not independently determine benefit coverage or provider reimbursement.

    Denial Risk

    Flag Experimental or Unproven Situations

    Kidney transplantation is considered experimental, investigational, and/or unproven in situations outside the covered clinical circumstances described in the policy.

    • Living- or deceased-donor kidney transplantation may be considered medically necessary for carefully selected individuals with end-stage renal disease.
    • Kidney retransplantation after a failed primary transplant may be considered medically necessary when the individual meets kidney-transplantation criteria.

    Policy Background

    Kidney transplantation is addressed for individuals with end-stage renal disease (ESRD), generally defined in this policy as a GFR of <15 mL/min/1.73 m². Potential medical necessity is recognized for carefully selected individuals receiving either a living-donor or deceased (cadaveric)-donor kidney transplant. Retransplantation after failure of a primary kidney transplant may also be medically necessary when kidney-transplantation criteria are met.

    Definitions

    End-Stage Renal Disease (ESRD)
    DefinitionInability of the kidneys to filter wastes and excess fluids from the blood
    Related conditionAlso known as chronic kidney disease stage 5
    GFR definitionGFR <15 mL/min/1.73 m²
    Chronic Kidney Disease Stage 4
    DefinitionChronic kidney disease with GFR from 15 to 29 mL/min/1.73 m²
    Disease stageStage 4 chronic kidney disease
    Transplant evaluationPatients with advanced chronic kidney disease, mainly stage 4 or stage 5, should be evaluated for transplant

    Kidney Transplant Candidate Criteria

    Kidney transplant candidate criteria

    A candidate must meet one of the medically necessary kidney-transplant pathways.

    ONE of the following candidate pathways

    • Initial kidney transplant

      • End-stage renal disease: The individual has end-stage renal disease.
      • Careful selection: The individual is carefully selected for transplantation.
      • ONE of the following donor types

        • Living donor.

    Contraindications

    Following transplantation, recipients require lifelong immunosuppression to prevent allograft rejection; rejection remains an important early and late complication risk that should be considered in assessing transplant suitability.

    Evaluation Requirements

    Documentation Required

    Complete the transplant evaluation

    Evaluate patients with advanced chronic kidney disease, particularly stage 4 or stage 5 disease, for kidney transplantation. Assess renal decline, symptoms, living-donor preferences, and anticipated waiting-list time when determining timing; dialysis is not required for consideration.

    • Stage 4 CKD: GFR 15 to 29 mL/min/1.73 m².
    • Stage 5 CKD/ESRD: GFR less than 15 mL/min/1.73 m².
    • After ESRD is diagnosed, determine whether the patient is suitable for transplantation.
    • Consider GFR or measured or estimated creatinine clearance and initiation of regular dialysis when calculating waiting time after listing.
    Policy Summary
    PayerHealthSpring
    PolicyKidney Transplant
    Policy CodePolicy SUR703.007
    Change TypeModified
    Effective DateMay 7, 2026
    Next Review DateN/A
    Key ActionReview the member’s benefit contract or Summary Plan Description for coverage, exclusions, and benefit limitations.
    SourceLink
    On This Page
    Kidney Transplant Coverage CriteriaCoding and Clinical ThresholdsProvider and Coverage ActionsPolicy BackgroundDefinitionsKidney Transplant Candidate CriteriaContraindicationsEvaluation Requirements
    Adult eGFR <10 mL/min/1.73 m²; pediatric eGFR 10 to 15 mL/min/1.73 m²

    Optimal timing also depends on the pace of renal decline, symptoms, and living-donor preferences.

    Timing considerationsRenal decline, symptoms, and living-donor preferences also affect optimal timing
    Pediatric Pre-emptive or Living-Donor Timing
    Pediatric timing rangeeGFR 10 to 15 mL/min/1.73 m²
    Applicable situationA living donor is available or pre-emptive deceased-donor transplantation is possible
    Timing considerationsOptimal timing also depends on renal decline, symptoms, and living-donor preferences
    End-Stage Renal Disease
    GFR threshold<15 mL/min/1.73 m²
    ConditionEnd-stage renal disease (ESRD)
    Clinical meaningKidneys are unable to perform their functions, including filtering wastes and excess fluids from the blood
    Advanced Chronic Kidney Disease Stage 4
    GFR range15 to 29 mL/min/1.73 m²
    ConditionAdvanced chronic kidney disease stage 4
    Clinical actionPatients with advanced chronic kidney disease should be evaluated for transplant
    End-Stage Renal Disease
    GFR threshold<15 mL/min/1.73 m²
    ConditionEnd-stage renal disease
    Transplant relevanceKidney transplant is an accepted treatment of end-stage renal disease
    Stage 4 Chronic Kidney Disease
    GFR range15 to 29 mL/min/1.73 m²
    ConditionChronic kidney disease stage 4
    Evaluation guidancePatients with advanced chronic kidney disease, mainly stage 4 or stage 5, should be evaluated for transplant
    Pre-emptive Transplant Threshold
    Common thresholdGFR below 15 mL/min/1.73 m²
    ProcedurePre-emptive kidney transplantation
    Timing limitationOptimal timing remains unclear
    Denial Risk

    Apply the Texas Organ-Sourcing Restriction

    For applicable Texas plans delivered, issued for delivery, or renewed on or after January 1, 2024, do not cover a human organ transplant or post-transplant care when the operation is performed in China or another country known to have participated in forced organ harvesting, or when the organ was procured through a sale or donation originating in such a country.

    • Forced organ harvesting includes removal of an organ from a living person through coercion, abduction, deception, fraud, or abuse of power or a position of vulnerability.
    • The Texas restriction applies to the plan types identified in the policy, including individual, student, small group, mid-market, large group, fully insured municipal/county/school, state employee, PPO, HMO, and POS plans.
    Denial Risk

    Evaluate Contraindications and Candidacy Risks

    Assess contraindications and potential contraindications through the transplant center’s clinical judgment before proceeding. These conditions may affect candidacy and the safety or likely success of transplantation.

    • Known current malignancy, including metastatic cancer.
    • Recent malignancy with a high risk of recurrence, or a history of cancer with a moderate risk of recurrence.
    • Systemic disease that could be exacerbated by immunosuppression.
    • Untreated systemic infection, including chronic infection, that makes immunosuppression unsafe.
    • Psychosocial conditions or chemical dependency affecting the ability to adhere to therapy.
    • Other irreversible end-stage diseases not attributed to kidney disease.
    Denial Risk

    Address Adherence and Substance-Use Concerns

    Document severe non-compliance and substance abuse as contraindications to kidney transplantation, while recognizing that these concerns may be overcome with clinician support and patient motivation. Evaluate whether psychosocial conditions or chemical dependency impair the patient’s ability to adhere to therapy.

    • Assess adherence history and readiness for the transplant regimen.
    • Document clinician support, treatment engagement, and patient motivation when addressing potentially remediable adherence or substance-use concerns.
    Denial Risk

    Flag Other Transplant Situations

    Do not treat kidney transplantation as covered when it falls outside the policy’s covered indications. Kidney transplant is experimental, investigational, and/or unproven in all other situations.

    • Covered clinical circumstances include carefully selected individuals with end-stage renal disease receiving a living- or deceased-donor transplant.
    • Kidney retransplantation after a failed primary transplant may be considered medically necessary when the individual meets kidney-transplantation criteria.
    Chronic Kidney Disease Stage 5
    DefinitionChronic kidney disease with GFR less than 15 mL/min/1.73 m²
    Disease stageStage 5 chronic kidney disease
    Relationship to ESRDESRD is also known as chronic kidney disease stage 5
    End-Stage Renal Disease (ESRD)
    Functional definitionInability of the kidneys to perform their functions
    Filtration functionIncludes filtering wastes and excess fluid from the blood
    Policy thresholdGFR less than 15 mL/min/1.73 m²
    Chronic Kidney Disease Stage 5
    GFR characterizationGenerally below 15 mL/min/1.73 m²
    ConditionChronic kidney disease stage 5
    Clinical contextStage 5 is among the advanced chronic kidney disease stages for which transplant evaluation should be considered
    Pre-emptive Kidney Transplantation (PEKT)
    DefinitionKidney transplantation performed before initiation of chronic dialysis
    AbbreviationPEKT
    Clinical rationaleIt avoids exposure to long-term dialysis therapy
    Pre-emptive Kidney Transplantation
    Procedure timingElective transplantation before chronic dialysis begins
    General GFR considerationGenerally recommended when GFR falls below 15 mL/min/1.73 m²
    Timing uncertaintyOptimal timing remains unclear
    Deceased donor: Deceased (cadaveric) donor.
  1. Kidney retransplant

    • Failed primary transplant: The primary kidney transplant has failed.
    • Meets transplant criteria: The individual meets criteria for kidney transplantation.
  2. Candidate evaluation

    Candidates may be evaluated before dialysis or before reaching the waiting-time calculation threshold.

    Kidney transplant candidate evaluation: Patients with advanced chronic kidney disease, mainly stages 4 and 5, should be evaluated for kidney transplantation.Stage 4: GFR 15 to 29 mL/min/1.73 m²; stage 5: GFR <15 mL/min/1.73 m²

    Dialysis is not required for consideration. Listing and transplant timing may be considered before GFR reaches 20 mL/min based on anticipated waiting-list time.

    Waitlist and allocation factors

    Allocation and waiting-list considerations include the following factors.

    Allocation factors: Kidney transplant candidates receive organ allocation points based on waiting time, age, donor-recipient immune-system compatibility, prior living-donor status, distance from the donor hospital, and survival benefit.

    These factors support allocation and prioritization and do not establish a mandatory medical listing criterion.

    Kidney transplant candidacy

    Clinical candidacy is assessed in the context of end-stage renal disease and overall suitability for transplantation.

    Kidney transplant candidacy: Kidney transplantation is an accepted treatment for end-stage renal disease, and patients with advanced chronic kidney disease, mainly stage 4 or stage 5, should be evaluated.ESRD: GFR <15 mL/min/1.73 m²; stage 4: GFR 15 to 29 mL/min/1.73 m²

    Dialysis is not required for consideration. Severe non-compliance and substance abuse are contraindications, but may be overcome with clinician support and patient motivation.

    Initial kidney transplant candidate

    May be considered medically necessary for a carefully selected individual with end-stage renal disease.

    Initial kidney transplant candidate: The individual has end-stage renal disease and is carefully selected for kidney transplantation.

    The donor may be living or deceased (cadaveric).

    Kidney retransplant candidate

    May be considered medically necessary after a failed primary kidney transplant when kidney-transplantation criteria are met.

    Kidney retransplant candidate: The individual has a failed primary kidney transplant and meets criteria for kidney transplantation.